NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIDDK E-132-2018-0-US-01 PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS US 62/719,492 Abandoned
NCI E-148-2011-0-EP-17 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer EP DIV 18188913.0 Issued
NCI E-148-2011-0-DE-43 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer DE EP 18188913.0 Issued
NCI E-148-2011-0-FR-45 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer FR EP 18188913.0 Issued
NCI E-148-2011-0-CH-42 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer CH EP 18188913.0 Issued
NCI E-148-2011-0-GB-46 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer GB EP 18188913.0 Issued
NCI E-148-2011-0-PT-50 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer PT EP 18188913.0 Issued
NCI E-148-2011-0-ES-44 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer ES EP 18188913.0 Issued
NCI E-148-2011-0-IT-48 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer IT EP 18188913.0 Issued
NCI E-148-2011-0-IE-47 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer IE EP 18188913.0 Issued
NCI E-148-2011-0-NL-49 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer NL EP 18188913.0 Issued
NCI E-148-2011-0-AT-40 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer AT EP 18188913.0 Issued
NCI E-148-2011-0-BE-41 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer BE EP 18188913.0 Issued
NHLBI E-175-2017-0-PCT-02 Hybrid CT System With Additional Detectors In Close Proximity To The Body PCT PCT PCT/US2018/046666 Expired
NCI E-136-2018-1-US-11 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab US National Stage 16/077,720 Pending
NLM E-111-2016-7-JP-05 Novel CRISPR Enzymes And Systems JP National Stage 2018-561180 Abandoned
NLM E-110-2016-2-JP-05 Novel CRISPR Enzymes And Systems JP National Stage 2018-561179 Pending
NLM E-110-2016-2-CN-06 Novel CRISPR Enzymes And Systems CN National Stage CN PCT/US2016/038238 Pending
NLM E-111-2016-7-CN-06 Novel CRISPR Enzymes And Systems CN National Stage CN PCT/US2016/038258 Pending
NIAID E-064-2016-1-IN-06 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS
AND THEIR USE 		IN National Stage 201817030203 Issued
NLM E-111-2016-7-EP-04 Novel CRISPR Enzymes And Systems EP National Stage 16742455.5 Issued
NLM E-111-2016-7-IE-01 Novel CRISPR Enzymes And Systems IE EP 16742455.5 Issued
NLM E-111-2016-7-IS-01 Novel CRISPR Enzymes And Systems IS EP 16742455.5 Issued
NLM E-111-2016-7-NL-01 Novel CRISPR Enzymes And Systems NL EP 16742455.5 Issued
NLM E-111-2016-7-LU-01 Novel CRISPR Enzymes And Systems LU EP 16742455.5 Issued
NLM E-111-2016-7-LI-01 Novel CRISPR Enzymes And Systems LI EP 16742455.5 Issued
NLM E-111-2016-7-BE-01 Novel CRISPR Enzymes And Systems BE EP 16742455.5 Issued
NLM E-111-2016-7-DK-01 Novel CRISPR Enzymes And Systems DK EP 16742455.5 Issued
NLM E-111-2016-7-CH-01 Novel CRISPR Enzymes And Systems CH EP 16742455.5 Issued
NLM E-111-2016-7-GB-01 Novel CRISPR Enzymes And Systems GB EP 16742455.5 Issued
NLM E-111-2016-7-DE-01 Novel CRISPR Enzymes And Systems DE EP 16742455.5 Issued
NLM E-111-2016-7-FR-01 Novel CRISPR Enzymes And Systems FR EP 16742455.5 Issued
NLM E-111-2016-7-FI-01 Novel CRISPR Enzymes And Systems FI EP 16742455.5 Issued
NLM E-111-2016-7-NO-01 Novel CRISPR Enzymes And Systems NO EP 16742455.5 Issued
NLM E-111-2016-7-SE-01 Novel CRISPR Enzymes And Systems SE EP 16742455.5 Issued
NLM E-110-2016-2-EP-04 Novel CRISPR Enzymes And Systems EP National Stage 16738253.0 Pending
NHGRI E-034-2019-0-US-01 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency US 62/177,771 Expired
NIAID E-064-2016-1-AU-02 RSV F IMMUNOGENS AND THEIR USE AU National Stage 2017242020 Issued
NCI E-051-2016-0-US-03 METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF APOPTOSIS INDUCING LIGANDS IN CANCER TREATMENT US National Stage 16/076,954 10849912 Issued PDF
NCI E-078-2016-0-US-03 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF US National Stage 16/076,878 Abandoned
NIEHS E-210-2017-0-EP-04 COMPOSITIONS AND METHODS FOR INHIBITING HIV-1
REVERSE TRANSCRIPTASE 		EP National Stage 18766424.8 Abandoned
NIEHS E-210-2017-0-PCT-02 Novel Strategy For Inhibiting HIV-1 Reverse Transcriptase PCT PCT PCT/US2018/045874 Expired
NIEHS E-210-2017-0-IL-05 Novel Strategy For Inhibiting HIV-1 Reverse Transcriptase IL National Stage 272409 Abandoned
NIEHS E-210-2017-0-CN-03 COMPOSITIONS AND METHODS FOR INHIBITING HIV-1
REVERSE TRANSCRIPTASE 		CN National Stage 2018800636827 Abandoned
NCI E-198-2018-0-US-01 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF US 62/716,169 Abandoned
NCI E-101-2016-0-US-05 GENE SIGNATURE PREDICTIVE OF HEPATOCELLULAR CARCINOMA RESPONSE TO TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) US National Stage 16/076,239 11306362 Issued PDF
NCI E-078-2012-0-EP-07 Anti-Mesothelin Chimeric Antigen Receptors EP DIV 18187755.6 Issued
NCI E-078-2012-0-FR-12 Anti-Mesothelin Chimeric Antigen Receptors FR EP 18187755.6 Issued
NCI E-078-2012-0-DE-13 Anti-Mesothelin Chimeric Antigen Receptors DE EP 18187755.6 Issued
NCI E-078-2012-0-GB-14 Anti-Mesothelin Chimeric Antigen Receptors GB EP 18187755.6 Issued